Skip to main content
Premium Trial:

Request an Annual Quote

Illumina's Q4 Revenues Leap 163 Percent as Profits Soar

NEW YORK (GenomeWeb News) — Illumina today said fourth-quarter revenues jumped 163 percent as R&D spending rose 17 percent and profit soared.
 
Total receipts for the three months ended Dec. 31, 2006, increased to $60.4 million from $23 million year over year.
 
R&D spending increased to $8.8 million from $7.5 million year over year.
 
The company said profit increased to $17.1 million from $326,000 in the year-ago period.
 
Illumina said it had around $130.7 million in cash, cash equivalents, and short-term investments as of Dec. 31.
 
The company said it expects 2007 revenue to be between $295 million and $315 million. First-quarter revenues are expected to be between $64 million and $68 million.
 
In the fourth quarter, Illumina completed the acquisition of Solexa for $600 million, and added two Solexa board members to its board.

The Scan

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.

Study Uncovers Genetic Mutation in Childhood Glaucoma

A study in the Journal of Clinical Investigation ties a heterozygous missense variant in thrombospondin 1 to childhood glaucoma.

Gene Co-Expression Database for Humans, Model Organisms Gets Update

GeneFriends has been updated to include gene and transcript co-expression networks based on RNA-seq data from 46,475 human and 34,322 mouse samples, a new paper in Nucleic Acids Research says.

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.